AstraZeneca plc (LON:AZN) had its price objective trimmed by Credit Suisse Group from GBX 5,000 ($65.11) to GBX 4,700 ($61.21) in a report published on Friday, July 28th, Marketbeat Ratings reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
AZN has been the subject of several other reports. Liberum Capital reiterated a buy rating and set a GBX 5,100 ($66.41) target price on shares of AstraZeneca plc in a report on Thursday, April 27th. Barclays PLC restated an overweight rating and issued a GBX 6,000 ($78.14) price objective on shares of AstraZeneca plc in a report on Friday, April 28th. UBS AG set a GBX 5,150 ($67.07) price objective on shares of AstraZeneca plc and gave the stock a neutral rating in a report on Tuesday, June 27th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.79) target price on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Saturday, May 20th. Finally, HSBC Holdings plc set a GBX 4,500 ($58.60) target price on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Tuesday, June 6th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 4,932.67 ($64.24).
AstraZeneca plc (LON AZN) opened at 4448.50 on Friday. The firm’s market capitalization is GBX 56.32 billion. The company’s 50-day moving average price is GBX 4,999.51 and its 200-day moving average price is GBX 4,862.78. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00.
The firm also recently announced a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.90) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.
In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($56.91) per share, for a total transaction of £1,704.30 ($2,219.43).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.